Two-Year Data Show Long-Term Benefits of Chronic Soliris® Therapy in Patients with aHUS
Alexion Pharmaceuticals, Inc. today announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris® therapy in patients with atypical hemolytic uremic syndrome , an ultra-rare genetic disease characterized by thro…
